ChrysCapital-backed fund crosses 5% stake in Bliss GVS Pharma via open market buy

Creeping Acquisition Near ThresholdOwnership Changes View source PDF Explain this filing

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.4%Reaction day

₹447.50

prior close

₹450.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.7%+4.1% vs market

Pharmaceuticals peers, median of 164sector-0.7%+4.1% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Microcap 250 and 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.2

15m

+0.7

30m

+1.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.4-0.7+4.1-0.7+4.1

Next day

+3.2-0.3+3.5-0.8+4.1

+2.0+1.1+1.0-0.1+2.1

+0.8-0.2+1.0-0.8+1.6

+1.7+0.2+1.4+0.0+1.6

+1.2-0.3+1.6-0.6+1.8

+3.5+2.1+1.4-0.3+3.8

15d

+14.9+4.6+10.3+2.4+12.5

+25.1+5.6+19.5+0.9+24.3

+56.2+7.2+49.0+3.9+52.3

+38.7-4.7+43.3-5.5+44.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Clarus Trust (managed by ChrysCapital Associates) bought 1,84,652 shares (0.17%) of Bliss GVS Pharma in the open market on July 20, 2026. Its holding along with PAC ClearEdge LLC rose from 4.95% to 5.13%, crossing the 5% disclosure threshold under SEBI Takeover Regulations. The acquirer is not a promoter of the company.

Likely market impact

A non-promoter institutional investor crossed the 5% stake threshold, signalling confidence. No mandatory open offer is triggered at this level.